Cargando…

JAK2 exon 12 mutation-positive myeloproliferative neoplasm associated with recurrent thromboembolism

Detalles Bibliográficos
Autores principales:	Tavakoli, Vahid, Naing, Sundee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2017
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5383592/ https://www.ncbi.nlm.nih.gov/pubmed/28401106 http://dx.doi.org/10.5045/br.2017.52.1.67

Ejemplares similares

MPL exon 10 mutations in Irish patients with a suspected myeloproliferative neoplasm
por: Lee Tokar, Lisa, et al.
Publicado: (2021)

The role of the Exon 13 G571S JAK2 mutation in myeloproliferative neoplasms
por: Bahar, Burak, et al.
Publicado: (2016)

The JAK2 gene as a protagonist in chronic myeloproliferative neoplasms
por: de Freitas, Renata Mendes, et al.
Publicado: (2013)

Mutations and deletions of the SUZ12 polycomb gene in myeloproliferative neoplasms
por: Brecqueville, M, et al.
Publicado: (2011)

JAK2 Exon 14 Deletion in Patients with Chronic Myeloproliferative Neoplasms
por: Ma, Wanlong, et al.
Publicado: (2010)

Calreticulin Exon 9 Mutations in Myeloproliferative Neoplasms
por: Ha, Jung-Sook, et al.
Publicado: (2015)

CALR mutations in myeloproliferative neoplasms: An unfolding story
por: Langabeer, Stephen E.
Publicado: (2020)

Non-driver mutations in myeloproliferative neoplasm-associated myelofibrosis
por: Li, Bing, et al.
Publicado: (2017)

JAK2V617F mRNA metabolism in myeloproliferative neoplasm cell lines
por: Nauroy, P, et al.
Publicado: (2014)

Effects of Mutational Combinations on Philadelphia-Negative Myeloproliferative Neoplasms
por: Ipek, Yonal-Hindilerden, et al.
Publicado: (2017)

Two Cases of Severe Hypertension in JAK2 Mutation-Positive Myeloproliferative Neoplasms
por: Rao, Raunak, et al.
Publicado: (2020)

Concurrent chronic myeloid leukemia and CALR-mutated myeloproliferative neoplasm
por: Langabeer, Stephen E.
Publicado: (2020)

Rare mutations in DNMT3A in myeloproliferative neoplasms and myelodysplastic syndromes
por: Brecqueville, M, et al.
Publicado: (2011)

Somatic mutations of calreticulin in a Brazilian cohort of patients with myeloproliferative neoplasms
por: Machado-Neto, João Agostinho, et al.
Publicado: (2015)

Concomitant JAK2 mutated myeloproliferative neoplasms and hereditary hemochromatosis
por: Loscocco, Giuseppe G., et al.
Publicado: (2022)

Hypercalcemia as a biomarker of myeloproliferative neoplasms?
por: Langabeer, Stephen E.
Publicado: (2019)

Dual Drivers in the Myeloproliferative Neoplasms: An Underestimation?
por: Langabeer, Stephen E.
Publicado: (2023)

Soluble interleukin-6 receptor in patients with JAK2V617F somatic mutation and myeloproliferative neoplasm
por: Garbers, Christoph, et al.
Publicado: (2020)

Tocilizumab and soluble interleukin-6 receptor in JAK2V617F somatic mutation and myeloproliferative neoplasm
por: Pedersen, Kasper Mønsted, et al.
Publicado: (2020)

Low-level somatic JAK2 V617F mutation in myelodysplastic/ myeloproliferative neoplasm with ring sideroblasts, and thrombocytosis with co-mutated SF3B1 and CALR
por: Ji, Young Sok, et al.
Publicado: (2022)

Myeloproliferative neoplasms: From JAK2 mutations discovery to JAK2 inhibitor therapies
por: Passamonti, Francesco, et al.
Publicado: (2011)

Resolution of thrombocytopenia, but not polycythemia after ruxolitinib for polycythemia vera with detectable mutation in the exon 12 of the JAK2 gene
por: Helbig, Grzegorz, et al.
Publicado: (2017)

Clinical significance of myeloproliferative neoplasms with JAK2V617F mutations and major BCR-ABL1 translocations: a literature review with case presentation
por: Kim, Bohyun, et al.
Publicado: (2020)

Germline and somatic JAK2 mutations and susceptibility to chronic myeloproliferative neoplasms
por: Goldin, Lynn R, et al.
Publicado: (2009)

Coexistence of JAK2 and BCR-ABL mutation in patient with myeloproliferative neoplasm
por: Hassan, Abdulaziz, et al.
Publicado: (2015)

Blast phase myeloproliferative neoplasm with prior exposure to ruxolitinib: comparative analysis of mutations and survival
por: Abdelmagid, Maymona G., et al.
Publicado: (2023)

Nontraumatic acute subdural hematoma associated with the myelodysplastic/myeloproliferative neoplasms
por: Ichimura, Shinya, et al.
Publicado: (2012)

Busulfan for the treatment of myeloproliferative neoplasms: the Mayo Clinic experience
por: Begna, K, et al.
Publicado: (2016)

Molecular Diagnostics with Laboratory Finding in Patients with Myeloproliferative Neoplasms
por: MAKANI, Zahra, et al.
Publicado: (2017)

CCND2 mutations are infrequent events in BCR-ABL1 negative myeloproliferative neoplasm patients
por: Cassinat, Bruno, et al.
Publicado: (2020)

Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms
por: De Stefano, Valerio, et al.
Publicado: (2018)

Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors
por: Helbig, Grzegorz
Publicado: (2018)

Mouse models of myeloproliferative neoplasms: JAK of all grades
por: Li, Juan, et al.
Publicado: (2011)

Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overview
por: de Freitas, Renata Mendes, et al.
Publicado: (2015)

JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders
por: Vainchenker, William, et al.
Publicado: (2018)

Modification of the Histone Landscape with JAK Inhibition in Myeloproliferative Neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2020)

JAK2 in Myeloproliferative Neoplasms: Still a Protagonist
por: Bader, Michael Stephan, et al.
Publicado: (2022)

Two Cases of Myeloproliferative Neoplasm with a Concurrent JAK2(V617F) Mutation and BCR/ABL Translocation without Chronic Myelogenous Leukemia Phenotype Acquisition during Hydroxyurea Treatment
por: Park, Sang Hyuk, et al.
Publicado: (2013)

Absence of JAK2V617F Mutated Endothelial Colony-Forming Cells in Patients With JAK2V617F Myeloproliferative Neoplasms and Splanchnic Vein Thrombosis
por: Guy, Alexandre, et al.
Publicado: (2020)

Hematopoietic fitness of JAK2(V617F) myeloproliferative neoplasms is linked to clinical outcome
por: Abu-Zeinah, Ghaith, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_m7jusum4q99uehmh2flmt8mt24